SignPath Pharma Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:SignPath Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10532
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SignPath Pharma Inc (SignPath) is a developer of therapeutics based on its pure synthesized curcumin compounds. The company’s curcumin compounds acts as an anti-oxidant, anti-inflammatory and anti-cell recycling agent. It develops curcumin based products in different intravenous nanoparticle-sized formulations such as liposomal, polymeric and PLGA. SignPath’s products find application in the treatment of cancers, neurologic disorders and mitigate drug-induced cardiac arrhythmia. The company conducts clinical trials for non-small cell lung cancer. It partners with laboratories, hospitals, and other companies in Canada, Europe, the US, and Asia. SignPath is headquartered in Quakertown, Pennsylvania, the US.

SignPath Pharma Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SignPath Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
SignPath Pharma to Acquire Patent Rights to Cardiac Arrhythmia Mitigation Drugs from Annie Bouchard 10
Venture Financing 11
SignPath Pharma Raises Additional USD2 Million in Financing Round 11
SignPath Pharma Raises USD0.3 Million in Financing Round 12
Licensing Agreements 13
SignPath Pharma Enters into Licensing Agreement with University of North Texas Health Science Center 13
SignPath Pharma Enters into Licensing Agreement with University of North Texas 14
Equity Offering 15
SignPath Pharma Raises USD3.3 Million in Second Tranche of Private Placement of Shares 15
SignPath Pharma Completes First Tranche Of Private Placement For US$1 Million 16
SignPath Pharma Completes Second Tranche Private Placement Of Series B Convertible Preference Stock For US$0.7 Million 17
SignPath Pharma Inc – Key Competitors 18
SignPath Pharma Inc – Key Employees 19
SignPath Pharma Inc – Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Key Facts 2
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SignPath Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SignPath Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
SignPath Pharma to Acquire Patent Rights to Cardiac Arrhythmia Mitigation Drugs from Annie Bouchard 10
SignPath Pharma Raises Additional USD2 Million in Financing Round 11
SignPath Pharma Raises USD0.3 Million in Financing Round 12
SignPath Pharma Enters into Licensing Agreement with University of North Texas Health Science Center 13
SignPath Pharma Enters into Licensing Agreement with University of North Texas 14
SignPath Pharma Raises USD3.3 Million in Second Tranche of Private Placement of Shares 15
SignPath Pharma Completes First Tranche Of Private Placement For US$1 Million 16
SignPath Pharma Completes Second Tranche Private Placement Of Series B Convertible Preference Stock For US$0.7 Million 17
SignPath Pharma Inc, Key Competitors 18
SignPath Pharma Inc, Key Employees 19

List of Figures
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SignPath Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[SignPath Pharma Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • General Cable Corp (BGC):企業の戦略的SWOT分析
    General Cable Corp (BGC) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Empresas Publicas De Medellin ESP-エネルギー分野:企業M&A・提携分析
    Summary Empresas Publicas De Medellin E.S.P. (EPM) is a decentralized body, operational under the ownership of Medellin municipality. It generates, transmits, and distributes electricity as well as undertakes gas distribution, wastewater and garbage treatment, and telecommunications services across …
  • Mylan Pharmaceuticals Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Mylan Pharmaceuticals Pvt Ltd (Mylan), a subsidiary of Mylan NV, is a pharmaceutical company that manufactures generic, speciality and active pharmaceutical ingredients (API). The company provides products such as critical care products, hepato care products, HIV care products, onco care pro …
  • EnGeneIC Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary EnGeneIC Ltd (EnGeneIC) is a biopharmaceutical company that develops drugs and other therapeutic molecules. The company develops nanocell platform used as a platform for the creation of custom therapies for cancer. Its cyto-immunotherapy platform releases concentrations of RNA-interference m …
  • Raley’s Family of Fine Stores:企業の戦略的SWOT分析
    Raley's Family of Fine Stores - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • CytoDel Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CytoDel Inc (CytoDel) is a biopharmaceutical company that utilizes molecular biology tools to produce recombinant derivatives of botulinum neurotoxin (BoNT). The company provides product portfolio such as Ctyo-111, an antidote to botulism; and Cyto-012 a recombinant BoNT derivative, among ot …
  • Pieridae Energy Ltd (PEA):石油・ガス:M&Aディール及び事業提携情報
    Summary Pieridae Energy Ltd (Pieridae Energy), formerly Petrolia Inc, is an oil and gas company that develops, explores, and produces oil resources. The company’s projects comprise Haldimand project, Bourque project, Tar Point project, Corte-Real project, Anticosti project, Dalhousie project; Edgar, …
  • Smiths Medical:企業の戦略的SWOT分析
    Smiths Medical - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • PetroTal Corp (TAL):石油・ガス:M&Aディール及び事業提携情報
    Summary PetroTal Corp (PetroTal), formerly known as Sterling Resources Ltd, is an oil and gas company that offers exploration, development and production of crude oil and natural gas properties. The company primarily operates in Bretana oil field in Peru, South America. PetroTal has operations in th …
  • Histocell SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Histocell SL (Histocell), a subsidiary of Noray Biosciences Group, is a biopharmaceutical company that develops cell therapy and tissue engineering products for regenerative medicine. The company provides Wharton Gel Complex, medical devices, contract manufacturing and cell therapy programs, …
  • BC Hydro-エネルギー分野:企業M&A・提携分析
    Summary BC Hydro (BC) is a government-owned hydroelectric utility company that generates, distributes and supply power. It is a provincial Crown corporation owned by the Province of British Columbia. Through its subsidiary, Powerex, it buys and sells wholesale power, renewable energy, financial ener …
  • Ferring International Center SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ferring International Center SA (Ferring) researches, develops and markets pharmaceutical products. The company offers pharmaceutical products in the fields of reproductive health, gastroenterology, endocrinology, urology and orthopedics. Some of the marketed products include Rekovelle (foll …
  • Hdfc Bank Ltd
    Hdfc Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Hdfc Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Perenco Holdings:企業の戦略的SWOT分析
    Perenco Holdings - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Nexstar Media Group, Inc. (NXST):企業の財務・戦略的SWOT分析
    Nexstar Media Group, Inc. (NXST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Cooper-Standard Holdings Inc.:企業の戦略・SWOT・財務分析
    Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Paramo AS:企業の戦略的SWOT分析
    Paramo AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Faxitron Bioptics LLC:医療機器:M&Aディール及び事業提携情報
    Summary Faxitron Bioptics LLC (Faxitron) is a medical device company that develops cabinet x-ray systems for specimen radiography, research and NDT applications. The company offers clinical products and lifescience products. Its clinical products include pathvision, corevision, biovision, localizer, …
  • DTE Energy Co (DTE):企業の財務・戦略的SWOT分析
    DTE Energy Co (DTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • SELEX Galileo Inc.:企業の戦略・SWOT・財務分析
    SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report Summary SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆